Trial · NCT02156843
Pyridorin in Diabetic Nephropathy
NCT02156843, Phase 3, Terminated, NephroGenex, Inc.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Pyridorin in Diabetic Nephropathy. Trials, record NCT02156843. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02156843
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pyridorin in Diabetic Nephropathy
- NCT number
- NCT02156843
- Status
- Terminated
- Phases
- Phase 3
- Enrollment
- 328 participants, actual
- Lead sponsor
- NephroGenex, Inc.
- Conditions
- Diabetic Nephropathy, Diabetic Kidney Disease
- Interventions
- Pyridorin, Placebo
- First posted
- 2014-06-05
- Last updated
- 2016-03-09
- Other registries' IDs
- eudract:2014-001641-24
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Time to composite endpoint of >=50% SCr increase from baseline or ESRD | Approximately 45 Months | Time to the composite endpoint consisting of the earliest event amongst a SCr increase of 50% from baseline that occurs during follow-up; or End Stage Renal Disease. ESRD is defined as the initiation of permanent dialysis, receiving a kidney transplant, or a SCr value \>= 6.0 mg/dL (530 umol/L) with a second SCr confirmation value \>=6.0 mg/dL (530 umol/L) obtained 4-6 weeks later. A confirmation of SCr value for subjects with ESRD and initiation of permanent dialysis or kidney transplant will not be collected. |
| Secondary | Time to the composite endpoint >=100% SCr increase or ESRD | Approximately 45 Months | A SCr increase of \>=100% that occurs during follow-up; or ESRD |
| Other | Change in serum cystatin-C | Change from baseline to Week 52 and from baseline to Week 104 | |
| Other | Change in urine protein/creatinine ratio (PCR) | From baseline to Week 52 and from baseline to Week 104 | |
| Other | Change in urinary transforming growth factor-beta (TGF-Beta) excretion | From baseline to Week 52 and from baseline to Week 104 | |
| Other | Change in SCr | From baseline to Week 52 and from baseline to Week 104 |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02156843
GET https://conductscience.org/api/trials/v1/NCT02156843/registered